The Conversation (0)
CytomX Therapeutics reported its financial business results for the third quarter of 2017.
CytomX Therapeutics (NASDAQ:CTMX) reported its financial business results for the third quarter of 2017.
As quoted in the press release:
As of September 30, 2017, CytomX had cash, cash equivalents and short-term investments of $331.3 million. Based upon its current operating plan, the Company expects its existing capital resources will be sufficient to fund operations into 2020.
“We have continued to enjoy a highly productive year with excellent progress in advancing our deep pipeline of potentially transformative Probody therapeutics and the addition of another major partner in Amgen,” said Sean McCarthy, D.Phil., president and chief executive officer of CytomX Therapeutics. “I am delighted with the team’s strong execution across all areas of the organization, and we continue to be well positioned for initial data read outs in 2018 from our lead, wholly owned programs, CX-072 and CX-2009. We also expect that Probody therapeutics targeting CTLA-4, PD-1, and CD71 will enter the clinic next year, demonstrating the considerable momentum behind our pipeline.”
Click here to read the full press release.
Source: www.marketwired.com
